NEW YORK, Dec. 10, 2024 /PRNewswire/ — Baird Medical Group (NASDAQ: BDMD), a leader in minimally invasive medical technologies, recently convened its 2024 Annual Review and 2025 Planning Meeting at the Baird Capital Tower in Guangzhou, China. The two-day event brought together executives, production leaders, and regional managers to reflect on the company’s achievements and plan for the year ahead.
On the first day, company leaders participated in the 7th Thyroid Disease Forum in Guangzhou, gaining insights into the latest advancements in thyroid treatment. These insights will inform marketing strategies and R&D initiatives in the coming year. Following the forum, leaders reviewed 2024 performance, highlighting market growth, innovations, and areas for improvement. Regional sales managers presented market reports and sales plans for 2025, setting a strong foundation for the upcoming year.
On the second day, Production Manager Le Zhang shared updates on product development progress and the 2025 production schedule, including plans to enhance after-sales service. Executives and managers discussed strategies to strengthen distributor relationships, ensuring alignment with Baird Medical’s global expansion goals.
In 2024, Baird Medical’s NASDAQ listing expanded its international recognition, positioning the company for further success in minimally invasive medical technologies. As the company enters 2025, Baird Medical remains committed to advancing in this field, confident in the team’s ability to drive innovation, achieve growth, and successfully execute its strategic vision for the year ahead.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/
SOURCE BDMD
SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI)…
The New Year Introduces Continuum's Entry-Level Tier, Starting at $25,000 Per YearNEW YORK, Dec. 22,…
BOSTON, Dec. 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with…
CHICAGO, Dec. 22, 2025 /PRNewswire/ -- TrustCommerce®, a Sphere company and leading provider of end-to-end…
MIAMI, Dec. 22, 2025 /PRNewswire/ -- BioFlorida, Inc. ("BioFlorida"), Florida's preeminent life sciences association, is…
Andreessen Horowitz leads the funding round which will accelerate the company's leadingtelehealth marketplaceAUSTIN, Texas, Dec.…